Abstract
Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2%), 264 (28·0%) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6%), stomachache (7·5%), nausea (3·6%), epigastric distress (2·1%) and abdominal distention (1·8%). More importantly, 246 participants (26·1%) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.
| Original language | English |
|---|---|
| Pages (from-to) | 719-722 |
| Number of pages | 4 |
| Journal | Journal of Clinical Pharmacy and Therapeutics |
| Volume | 34 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2009 Dec 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Adverse effect
- Erythromycin
- Infection control team
- Outbreak
- Pertussis
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis. / Tanaka, H.; Kaji, M.; Higuchi, K.; Shinohara, N.; Norimatsu, M.; Kawazoe, Hitoshi; Ninomiya, M.; Fukuoka, N.; Ishii, N.; Fujita, J.; Okabe, A.; Houchi, H.
In: Journal of Clinical Pharmacy and Therapeutics, Vol. 34, No. 6, 01.12.2009, p. 719-722.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Problems associated with prophylactic use of erythromycin in 1566 staff to prevent hospital infection during the outbreak of pertussis
AU - Tanaka, H.
AU - Kaji, M.
AU - Higuchi, K.
AU - Shinohara, N.
AU - Norimatsu, M.
AU - Kawazoe, Hitoshi
AU - Ninomiya, M.
AU - Fukuoka, N.
AU - Ishii, N.
AU - Fujita, J.
AU - Okabe, A.
AU - Houchi, H.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2%), 264 (28·0%) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6%), stomachache (7·5%), nausea (3·6%), epigastric distress (2·1%) and abdominal distention (1·8%). More importantly, 246 participants (26·1%) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.
AB - Background and objective: Pertussis developed in Kagawa University Medical School and University Hospital in May 2007. To control the outbreak and prevent the infection of hospital inpatients, the Infection Control Team (ICT) carried out the prophylactic administration of erythromycin (EM) to hospital staff (1566 staff) who might be exposed to Bordetella pertussis. Methods: An oral dose of 1000 mg/day EM was given for 10 days. To assess compliance and estimate the frequency of adverse effect, the ICT conducted a questionnaire survey. Results and discussion: Of 942 respondents (response rate: 60·2%), 264 (28·0%) experienced some form of EM adverse effects, of which the most commonly reported involved digestive organ symptoms, e.g. diarrhoea (15·6%), stomachache (7·5%), nausea (3·6%), epigastric distress (2·1%) and abdominal distention (1·8%). More importantly, 246 participants (26·1%) stopped taking the EM before completing 10 days because of perceived adverse effects. Conclusion: These results indicate that EM appears to cause adverse effects more frequently than reported in the package insert in Japan. The prophylactic use of EM for pertussis infection is recognized in the guideline of the Centers for Disease Control and Prevention. However, this study suggests that attention should be paid to EM non-compliance during a pertussis outbreak, which could extend the duration of the outbreak and increase the number of affected patients.
KW - Adverse effect
KW - Erythromycin
KW - Infection control team
KW - Outbreak
KW - Pertussis
UR - http://www.scopus.com/inward/record.url?scp=70450171362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70450171362&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2710.2009.01060.x
DO - 10.1111/j.1365-2710.2009.01060.x
M3 - Article
C2 - 20175806
AN - SCOPUS:70450171362
VL - 34
SP - 719
EP - 722
JO - Journal of Clinical Pharmacy and Therapeutics
JF - Journal of Clinical Pharmacy and Therapeutics
SN - 0269-4727
IS - 6
ER -